Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ripal Gandhi

Vascular & Interventional Radiology Miami, FL Medical Doctor

NPI 1417150764 CMS profile 245348

8900 N Kendall Dr, Miami, FL 33176

Open in the dashboard

General payments

$2,536,636

3,956 records reported · program years 2019–2025

Research payments

$9,181

Paid to them · 12 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$329,488 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Ripal Gandhi of Miami, FL is reported in the CMS Open Payments database as having received $2,536,636 across 3,956 general payments and $9,181 in research payments paid to them. Separately, studies naming them as principal investigator received $329,488 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $441,022 584
2025 Research $1,050 2
2024 General $464,530 638
2024 Research $3,381 6
2023 General $444,121 567
2023 Research $475 1
2022 General $294,041 510
2021 General $253,842 479
2021 Research $450 1
2020 General $270,480 467
2020 Research $225 1
2019 General $368,599 711
2019 Research $3,600 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ripal Gandhi
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Ripal Gandhi were reported at $441,022. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Ripal Gandhi Vascular & Interventional Radiology median Middle half National median
2019 $368,599 $422 $125–$1,555 $163
2020 $270,480 $200 $68–$652 $114
2021 $253,842 $280 $99–$866 $132
2022 $294,041 $433 $137–$1,497 $149
2023 $444,121 $506 $152–$2,019 $160
2024 $464,530 $556 $175–$1,930 $164
2025 $441,022 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sirtex Medical Inc $1,752,588 2,661 payments
  2. Inari Medical, Inc. $340,326 280 payments
  3. Stryker Corporation $90,389 64 payments
  4. Medtronic, Inc. $51,881 147 payments
  5. Surefire Medical, Inc. $43,466 77 payments
  6. Penumbra, Inc. $37,683 101 payments
  7. Bard Peripheral Vascular, Inc. $35,057 62 payments
  8. Medtronic Vascular, Inc. $32,975 62 payments
  9. Boston Scientific Corporation $25,852 91 payments
  10. Balt USA, LLC $19,098 36 payments
  11. Other $107,321 375 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,499,447 610 payments
  2. Consulting Fee $422,735 252 payments
  3. Honoraria $308,565 131 payments
  4. Travel and Lodging $210,719 1,320 payments
  5. Food and Beverage $94,677 1,640 payments
  6. Education $492 3 payments
Products named General payments · program years 2019–2025
  1. SIR-Spheres Microspheres $1,723,762 2,601 payments
  2. FLOWTRIEVER CATHETER, S $429,583 329 payments
  3. CT THROMBECTOMY SYSTEM KIT $418,005 314 payments
  4. TRINAV INFUSION SYSTEM $37,745 67 payments
  5. LAVA LES (Liquid Embolic System) $28,826 60 payments
  6. Indigo System $21,580 57 payments
  7. TECENTRIQ $18,603 24 payments
  8. TheraSphere Y90 Glass Microspheres 10 GBq $16,701 40 payments
  9. Eye90 microspheres $15,174 20 payments
  10. RUBY Coil $13,496 19 payments
  11. Other $133,346 665 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $3,825 2 payments
  2. ABK Biomedical USA, Inc. $3,381 6 payments
  3. Medtronic, Inc. $1,975 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

60

Median for Diagnostic Radiology: 24

Drug cost

$273

Median for Diagnostic Radiology: $190

Branded share of claims

0%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 22 $141
Levofloxacin Generic 24 $69
Pantoprazole Sodium Generic 14 $63

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 111 billing codes

Paid by Medicare

$62,953

Medicare's payments for the services billed

Medicare patients

272

Average age 76

Services billed

1,083

150 women, 122 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 56%
Diabetes 44%
Chronic kidney disease 44%
Heart failure 34%
COPD 33%
Cancer 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TECENTRIQ
$11 — —
Avastin
$11 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

3,968 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record